# OMNIlife science

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/omnilife-science

- Industry: Medical Devices & Equipment
- Headquarters: Raynham, US
- Website: www.omnils.com
- Total disclosed funding: $4.8M
- Latest round: Series A (Jan 23, 2009)
- Investors on record: 1

## About

OMNIlife science, Inc. specializes in orthopedic solutions, focusing on innovative technologies to enhance surgical outcomes and patient recovery in joint replacement procedures.OMNIlife science, Inc. is a provider of orthopaedic solutions, focusing on enhancing surgical outcomes through innovative technology. The company was founded in 1999 and is headquartered in Raynham, Massachusetts, US. In March 2019, Corin Group PLC, a portfolio company of Permira, completed the acquisition of OMNIlife science, Inc. from Pioneer Capital Partners for undisclosed financial terms. Cheryl Williams is the CEO of the company. OMNIlife science has been involved in 6 investment deals with the most recent deal occurring on March 6, 2019. The company has raised a total of USD 15.06 mn, with the latest funding round being a VENTURE DEBT round amounting to USD 27.50 mn.OMNIlife science, Inc. specializes in innovative orthopaedic technologies that improve joint replacement procedures. Their flagship offerings include the Apollo platform and ApolloKnee software application, both receiving USA FDA 510(k) clearance, EU MDR approval, and AU TGA registration. These advancements facilitate precise planning and implementation in robotic-assisted surgeries, catering to healthcare providers and surgeons to achieve optimal patient outcomes in the orthopedic sector.OMNIlife science, Inc. generates revenue through sales of its advanced orthopaedic products and technologies, particularly focusing on business-to-business transactions. The sales primarily involve the Apollo platform, ApolloKnee software, and related implant products. Specific revenue figures are not disclosed, but the company's transaction model positions it to benefit from partnerships with hospitals, enhancing the integration of its technologies into surgical practices.Looking ahead, OMNIlife science, Inc. is poised to leverage its recent acquisition by Corin Group to expand its product offerings and market reach. Following the acquisition completed in March 2019, the company is expected to introduce new products aimed at enhancing surgical precision and recovery in joint replacement procedures. Furthermore, OMNIlife science plans to penetrate new geographic markets, specifically targeting regions in Europe and Australia by leveraging Corin's established infrastructure. The recent VENTURE DEBT funding of USD 27.50 mn will be allocated towards product development and marketing initiatives to support these expansion strategies.

## Funding rounds

- Series A, Jan 23, 2009, $4.8M — Pioneer Capital

## Investors

- Pioneer Capital (https://capitalatlas.ai/funds/pioneer-capital) — Series A